Advertisement

Topics

Sobi Receives Approval from Health Canada for Once-Daily Dosing of Orfadin® (nitisinone) for the Treatment of HT-1

08:00 EDT 17 Apr 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
- First and only nitisinone product in Canada approved for once-daily use, designed to meet the needs of HT-1 patients entering older childhood, adolescence and adulthood - Sobi, a pioneering international biopharmace...

Other Sources for this Article

Sobi
Trista Morrison, 781-810-0490
trista.morrison@sobi.com

NEXT ARTICLE

More From BioPortfolio on "Sobi Receives Approval from Health Canada for Once-Daily Dosing of Orfadin® (nitisinone) for the Treatment of HT-1"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...